Junshi reports positive final phase 3 NEOTORCH readout: full analysis

Junshi Biosciences has reported that the phase 3 NEOTORCH trial met its primary endpoints in the final analysis of perioperative toripalimab plus platinum-containing doublet chemotherapy for patients with resectable stage II-III NSCLC. The company disclosed on May 26, 2026 that event-free survival and major pathologic response were positive in the overall stage II-III population, while major pathologic response also met the prespecified boundary in stage III disease. Junshi said it now plans to submit a supplemental new drug application aimed at expanding toripalimab’s perioperative indication in China. (globenewswire.com)

This update builds on a multiyear development program around toripalimab, Junshi’s anti-PD-1 antibody. NEOTORCH is a randomized, double-blind, placebo-controlled phase 3 trial, registered as NCT04158440, that enrolled 501 patients with resectable stage II-III NSCLC across 50 hospitals in China. According to the previously published JAMA paper, the trial was designed to test perioperative toripalimab plus chemotherapy against chemotherapy alone, with hierarchical testing across event-free survival, major pathologic response, and overall survival in stage III and stage II/III populations. (globenewswire.com)

The background here matters. In January 2023, Junshi reported that a prespecified interim analysis had already met the event-free survival endpoint in resectable stage III NSCLC. Those data were later published in JAMA in January 2024, where investigators reported median event-free survival was not reached with toripalimab plus chemotherapy versus 15.1 months with chemotherapy alone, corresponding to a hazard ratio of 0.40. The same report showed substantially higher pathologic complete response and major pathologic response rates in the toripalimab arm. Based on those interim data, China’s National Medical Products Administration approved toripalimab in January 2024 for perioperative treatment, followed by adjuvant monotherapy, in adults with resectable stage IIIA-IIIB NSCLC. (globenewswire.com)

In the new company announcement, Junshi did not release the full final-analysis numbers for the broader stage II-III population, but it did say the prespecified efficacy boundary was met for event-free survival and major pathologic response in that group. It also said the major pathologic response endpoint was met in the stage III subgroup and that the full primary-endpoint results will be presented at an upcoming international academic conference. That means the topline is clearly positive, but clinicians and analysts still need the mature hazard ratios, confidence intervals, subgroup breakdowns, safety detail, and overall survival update before judging how practice-changing the broader stage II-III expansion may be. (globenewswire.com)

Independent expert reaction to this exact final readout was limited in early coverage, but the earlier NEOTORCH results had already drawn attention because they placed toripalimab among the checkpoint inhibitors moving into perioperative NSCLC. The ASCO Post highlighted the interim phase 3 data in 2023 as showing significant event-free survival improvement in operable stage III NSCLC, underscoring the study’s relevance in a fast-moving perioperative treatment landscape. In that sense, today’s announcement is less a surprise than a confirmation that the trial’s benefit appears to hold up as follow-up matures and the analysis expands to the full intended stage II-III population. (ascopost.com)

Why it matters: For veterinary professionals, the direct clinical implications are limited because this is a human oncology study, but the translational signal is notable. Comparative oncology increasingly watches how immunotherapy is used not only in metastatic disease, but also around surgery, where the goals include shrinking disease, improving resectability, and reducing recurrence risk. NEOTORCH also reinforces a broader development pattern: pathologic response endpoints and event-free survival are becoming central tools for moving immunotherapies into earlier-stage settings. That trend can influence how veterinary oncology researchers think about trial design, biomarker strategy, and the timing of systemic therapy in solid tumors, even when the specific drug and indication aren’t directly transferable. (globenewswire.com)

There’s also a regulatory and market angle. Toripalimab already has a stage III perioperative approval in China, so this filing is positioned as a label expansion rather than a first approval in the setting. If regulators agree that the final analysis supports benefit in stage II disease as well, Junshi could broaden the eligible patient population and strengthen toripalimab’s role in a competitive perioperative NSCLC field. Internationally, toripalimab is already marketed in multiple regions for other indications, but this specific perioperative NSCLC expansion appears to be centered on Chinese regulators for now. (globenewswire.com)

What to watch: The next key milestones are the full conference presentation of the final NEOTORCH data, details of Junshi’s supplemental filing timeline, and whether the mature dataset shows a convincing overall survival trend and manageable perioperative safety profile across the broader stage II-III population. (globenewswire.com)